Skip to main content

Table 1 Antidepressants and cognitive decline by dementia subtypes

From: Antidepressant use and cognitive decline in patients with dementia: a national cohort study

Dementia disorders

β (95%CIs)

P

All dementias (n = 18,740)

 − 0.30 (− 0.39, − 0.21)

 < .001

AD and mixed (n = 11,415)a

 − 0.28 (− 0.40, − 0.16)

 < .001

VaD (n = 2194)

 − 0.27 (− 0.52, − 0.02)

0.037

LBD (n = 587)a

 − 0.09 (− 0.65, 0.47)

0.759

FTD (n = 201)

1.28 (− 0.11, 2.66)

0.072

Other dementias (n = 4343)

 − 0.34 (− 0.52, − 0.16)

 < .001

  1. Adjusted for age, sex, calendar year of diagnosis, the type of dementia, Mini-Mental State Examination score at diagnosis, coresident status, care unit, depression, fracture, Charlson Comorbidity Index score, medications (angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), β-blocking agents, calcium channel blockers, nonsteroidal anti-inflammatory drugs, diuretics, lipid-modifying agents, antiplatelets, antipsychotics, anxiolytics, and hypnotics)
  2. Abbreviations: SveDem the Swedish Registry for Cognitive/Dementia Disorders, CIs Confidence intervals, AD Alzheimer’s disease, Mixed Mixed dementia, VaD Vascular dementia, LBD Parkinson’s disease with dementia and dementia with Lewy bodies, FTD Frontotemporal dementia
  3. aFurther adjusted for cholinesterase inhibitors and memantine
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us